Chunbai He
About Chunbai He
Chunbai He is the Associate Director of Pipeline, Asset & Governance Analytics at Bristol Myers Squibb, specializing in cardiovascular analytics and health economics and outcomes research.
Title
Chunbai He is the Associate Director, Pipeline, Asset & Governance Analytics at Bristol Myers Squibb. In this role, Chunbai He specializes in cardiovascular analytics and focuses on pipeline, asset, and governance analytics.
Current Role at Bristol Myers Squibb
At Bristol Myers Squibb, Chunbai He plays a significant role in overseeing pipeline, asset, and governance analytics. His work primarily revolves around cardiovascular analytics, where he assesses the value of new therapies and strives to expand innovative treatment options to improve patient outcomes.
Professional Experience and Background
Chunbai He has extensive experience in the pharmaceutical and healthcare research sectors. Prior to his current role, he worked as a Student Intern at ATOMS VC in 2022. He also held the position of Research Specialist at the University of Chicago from 2020 to 2022, Scientific Lead at Coordination Pharmaceuticals Inc from 2020 to 2022, Senior Scientist in Product Development at Fresenius Kabi USA from 2017 to 2020, Research Professional at the University of Chicago from 2015 to 2017, and Postdoc at the University of Chicago from 2013 to 2015.
Education and Expertise
Chunbai He has an impressive academic background. He earned his MBA from The University of Chicago Booth School of Business (2020-2023), a Master's degree in Health Services and Outcomes Research from Northwestern University (2018-2020), a Ph.D. in Genetic Engineering; Pharmaceutical Sciences from Fudan University (2007-2012), and a Bachelor's degree in Biotechnology from Fudan University (2003-2007). He has developed strong expertise in health economics and outcomes research (HEOR), regulatory affairs, and bridging the gap between lab innovations and commercial pharmaceuticals.
Focus Areas and Contributions
Chunbai He has made significant contributions to the field of healthcare and pharmaceuticals. With a focus on cardiovascular analytics, he excels in pipeline, asset, and governance analytics. His expertise in health economics and outcomes research (HEOR) is critical for evaluating the value of new therapies. Furthermore, he has a robust background in regulatory affairs, essential for pharmaceutical approvals. His dedication to expanding new therapy options underscores his commitment to enhancing patient outcomes through innovative treatments.